Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 139Carcinoma, Non-Small-Cell Lung 109Prostatic Neoplasms 51Lung Neoplasms 31Neoplasm Metastasis 21Stomach Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Nasopharyngeal Carcinoma 16Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Esophageal Neoplasms 11Head and Neck Neoplasms 8Esophageal Squamous Cell Carcinoma 8Urinary Bladder Neoplasms 7HER2-positive Breast Cancer 7Ovarian Neoplasms 6Carcinoma 6Adenocarcinoma 6Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma of Lung 5Triple Negative Breast Neoplasms 4Recurrence 4Carcinoma, Transitional Cell 4Adenocarcinoma Of Esophagus 4Primary Breast Cancer 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma, Bronchiolo-Alveolar 3

Interventions

S 1 (combination) 1Immunotherapy, Adoptive 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gastric Adenocarcinoma × Docetaxel × Clear all
NCT01283217 2013-06-04

Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer

Yonsei University

Phase 3 Unknown
166 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡